All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the International Symposium on Hodgkin Lymphoma (ISHL) 2022 meeting, the Lymphoma Hub spoke with Astrid Pavlovsky, Fundaleu, Buenos Aires, AR. We asked, When and how should treatment be modified for older patients with HL?
When and how should treatment be modified for older patients with HL?
Pavlovsky begins by outlining why patients with HL >60 years of age typically have poor outcomes compared with younger patients. Pavlovsky then discusses the challenges faced when treating older patients with HL and reviews the latest clinical trial data for novel agents and combination therapies in this difficult-to-treat population.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Real-world outcomes of very elderly lymphoma patients in Sweden
The results of this real-world analysis in Swedish very elderly lymphoma patients, indicate that in DLBCL and MZL current active treatments offer a significantly superior survival...
Should age affect eligibility for autologous stem cell transplant in elderly lymphoma patients?
This study demonstrated that elderly patients are still viable candidates for ASCT, with good clinical outcomes and acceptable expected toxicities.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox